NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 3 நாட்களுக்கு முன்இன்று 57 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Indo Borax and Zenrock Chemicals Open Offer for Kronox Lab Sciences Commenced on November 6, 2026
IIFL Capital Services has submitted the Offer Opening Public Announcement cum Corrigendum for the open offer targeting Kronox Lab Sciences Limited. The open offer is being executed by Acquirer Indo Borax and Chemicals Limited alongside Person Acting in Concert (PAC) Zenrock Chemicals Private Limited pursuant to Regulations 3(1) and 4 of SEBI (SAST) Regulations. The tendering period for public shareholders officially commenced on November 6, 2026. Prior statutory milestones include the Public Announcement on August 20, 2026, and the Letter of Offer dispatch on October 29, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe open offer by Indo Borax and Chemicals Limited and Zenrock Chemicals for Kronox Lab Sciences has officially opened for tendering as of November 6, 2026.
ஏன் இது முக்கியம்A successful takeover or substantial share acquisition triggers a potential change in control or entry of a strategic co-promoter, altering the company's long-term governance and chemical business synergies.
Tendering Period Start Date: நவம்பர் 6, 2026Public Announcement Date: ஆகஸ்ட் 20, 2026Detailed Public Statement Date: ஆகஸ்ட் 28, 2026Letter of Offer Date: அக்டோபர் 29, 2026
📅 குறுகிய காலம்Share price action may align closely with the open offer price during the active tendering window.
📈 நீண்ட காலம்Substantial acquisition of equity shares could result in ownership changes and strategic operational integration with Indo Borax and Chemicals.
⚠ அபாய எச்சரிக்கைகள்
Potential change of management/control risks
Acceptance ratio uncertainty for tendering shareholders
👀 கவனிக்க வேண்டியவை
Track the tendering period timeline and the final offer pricing details in the Letter of Offer to decide on participation or evaluate the potential shift in post-offer ownership structure.
Indo Borax Launches Open Offer for 25.79% Stake in Kronox Lab at ₹157.27/Share
Indo Borax and Chemicals Limited, along with Zenrock Chemicals Private Limited (PAC), has submitted the Letter of Offer to acquire up to 95,70,000 equity shares (25.79% voting capital) of Kronox Lab Sciences Limited from public shareholders. The open offer price is fixed at ₹157.27 per equity share, payable in cash, totaling up to approximately ₹150.51 crore. The offer price of ₹157.27 trades at a discount to the current market price of ₹190.00. The open offer follows compliance with SEBI SAST Regulations pursuant to a substantial acquisition and change in control.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndo Borax and Chemicals has finalized and dispatched the formal Letter of Offer for its mandatory open offer to acquire up to 25.79% of Kronox Lab Sciences.
ஏன் இது முக்கியம்A successful takeover will result in Indo Borax gaining a significant or controlling stake in Kronox Lab Sciences, potentially reshaping capital allocation, management, and operational synergies in high-purity chemicals.
Offer Price: ₹157.27 per shareShares to acquire: 95,70,000Offer Stake: 25.79%Estimated Offer Size: ₹150.51 கோடிOffer Size vs Net Worth: ~117.6%
📅 குறுகிய காலம்Because the offer price of ₹157.27 is below the current market price of ₹190.00, public shareholder tendering acceptance may remain limited unless open market prices correct or the price is revised.
📈 நீண்ட காலம்Strategic integration with Indo Borax could alter business direction, governance, and expansion plans including the ongoing Unit-IV Dahej project.
⚠ அபாய எச்சரிக்கைகள்
Offer price trades at a discount to prevailing market price
Potential changes in board composition and management control post-acquisition
👀 கவனிக்க வேண்டியவை
Track the tendering period dates and monitor the Independent Directors' committee recommendations on whether the ₹157.27 offer price is fair relative to market trading levels (₹190.00).
Kronox Lab Q2 PAT Dips 3.5% YoY to ₹6.44 Cr; Indo Borax Takes Controlling 64.26% Stake
Kronox Lab Sciences reported a modest 5.1% YoY increase in Q2 FY27 revenue from operations to ₹26.83 Cr compared to ₹25.53 Cr in Q2 FY26, though revenue fell 5.5% sequentially. Net profit for the quarter declined 3.5% YoY to ₹6.44 Cr from ₹6.68 Cr, impacted by higher other expenses. For H1 FY27, revenue rose 10.8% YoY to ₹55.22 Cr with PAT up 5.2% to ₹13.74 Cr. Crucially, the filing highlights the completion of Indo Borax & Chemicals acquiring a 64.26% controlling stake on September 29, 2026, leading to a reconstituted Board and top management.
உச்சம் நம்பிக்கை
என்ன மாறியதுKronox Lab reported Q2/H1 FY27 financial performance and confirmed Indo Borax & Chemicals became the holding company following a 64.26% stake transfer on September 29, 2026.
ஏன் இது முக்கியம்Operational earnings show moderate top-line growth but margin pressure, while the change in promoter control to Indo Borax may reshape long-term governance, capital allocation, and business synergies.
Q2 Revenue from Operations: ₹2,683.42 லட்சம்Q2 Profit After Tax: ₹644.03 லட்சம்H1 Net Cash from Operations: ₹1,604.13 லட்சம்Promoter Stake Transferred to Indo Borax: 64.26%Total Equity (Net Worth): ₹12,798.64 லட்சம்
📅 குறுகிய காலம்Subdued sequential earnings and flat year-on-year PAT growth may temper near-term momentum, though debt reduction to nil remains a positive factor.
📈 நீண்ட காலம்The structural narrative hinges on how the new parent company, Indo Borax, executes on pending capex (such as UNIT-IV at Dahej) and leverages synergies in fine chemicals.
⚠ அபாய எச்சரிக்கைகள்
Integration and leadership transition risks following change in control
Sequential contraction in quarterly margins and operating profit
👀 கவனிக்க வேண்டியவை
Track details of the upcoming Postal Ballot resolutions and strategic updates from the newly appointed management under parent company Indo Borax & Chemicals.
Indo Borax and Zenrock Launch Open Offer to Acquire 25.79% Stake in Kronox Lab Sciences
Indo Borax and Chemicals Limited, together with Zenrock Chemicals Private Limited (PAC), has launched an open offer to acquire up to 95,70,000 equity shares of Kronox Lab Sciences Limited. This represents 25.79% of the target company's total voting share capital under SEBI (SAST) Regulations. Kronox Lab Sciences informed exchanges that the committee of independent directors published their recommendations regarding the offer in national newspapers on November 3, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndo Borax and Chemicals, along with PAC Zenrock Chemicals, initiated a formal open offer to purchase a 25.79% public stake in Kronox Lab Sciences.
ஏன் இது முக்கியம்A 25.79% equity acquisition signals potential substantial changes in shareholding or strategic control, which could alter corporate governance and operational direction.
Shares to be acquired: 95,70,000Stake size (% of voting capital): 25.79%ஒரு பங்கின் முக மதிப்பு: ₹10.00Publication date: நவம்பர் 03, 2026
📅 குறுகிய காலம்Share price may react based on the offer price relative to the prevailing market price of Rs 199.7.
📈 நீண்ட காலம்Potential strategic involvement or board presence from Indo Borax could influence future capital allocation and synergies in the specialty chemicals business.
⚠ அபாய எச்சரிக்கைகள்
Uncertainty around final acceptance ratio for tendering public shareholders
Potential shifts in management oversight or strategic direction
👀 கவனிக்க வேண்டியவை
Track the detailed Independent Directors' recommendation report, the formal letter of offer, and the specific open offer price to evaluate whether to tender shares.
Kronox SPA Amended: Lock-in and ROFR Removed on Sellers' Remaining 9.95% Stake
Kronox Lab Sciences informed exchanges of an amendment to the Share Purchase Agreement (SPA) dated August 20, 2026, executed between purchaser Indo Borax and Chemicals, erstwhile promoters (Sellers), and Zenrock Chemicals. Indo Borax had acquired up to 2,38,44,000 equity shares (64.26% stake), taking over promoter control effective September 29, 2026. Under the amendment signed on October 22, 2026, the lock-in restrictions and Right of First Refusal (ROFR) governing the Sellers' remaining 9.95% stake were deleted. This frees the erstwhile promoters to sell their residual holdings in the open market.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe SPA governing the acquisition of Kronox by Indo Borax was altered to remove lock-in and ROFR conditions on the 9.95% stake retained by the former promoters.
ஏன் இது முக்கியம்The deletion of lock-in and ROFR allows the erstwhile promoters to offload their remaining 9.95% equity stake at will, potentially creating short-term supply overhang in the market.
Controlling stake acquired by Indo Borax: 64.26%Shares acquired under SPA: up to 2,38,44,000Residual stake held by Sellers: 9.95%Date of amendment agreement: அக்டோபர் 22, 2026
📅 குறுகிய காலம்Watch for supply overhang or block trades as the erstwhile promoters can now sell up to 9.95% of the company's equity without lock-in or ROFR restrictions.
📈 நீண்ட காலம்Limited operational impact; Indo Borax remains firmly in control with a 64.26% promoter holding, and long-term performance hinges on UNIT-IV Dahej execution.
⚠ அபாய எச்சரிக்கைகள்
Potential market overhang from prospective divestment of the 9.95% stake by erstwhile promoters
👀 கவனிக்க வேண்டியவை
Monitor secondary market block deals or insider trading disclosures for potential stake sales by erstwhile promoters holding 9.95% of shares.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Kronox Lab Sciences to Acquire 5,000 Sq. Meter Plant in Dahej SEZ from Axiom Chemicals
Kronox Lab Sciences' Board has approved the acquisition of a manufacturing plant admeasuring approximately 5,000 sq. meters located at Dahej SEZ from Axiom Chemicals Private Limited. The transaction is structured as an asset acquisition rather than an equity buyout and will be funded entirely through internal accruals. The acquisition is targeted for completion within one month, subject to regulatory clearances including approvals from the Development Commissioner / SEZ authority and pollution control boards. Specific financial consideration for the transaction was not disclosed.
உச்சம் நம்பிக்கை
என்ன மாறியதுKronox Lab Sciences approved the cash acquisition of a 5,000 sq. meter chemical manufacturing plant in Dahej SEZ from Axiom Chemicals.
ஏன் இது முக்கியம்This adds physical plant capacity in the Dahej chemical hub to support business growth and expansion, complementing the company's broader Dahej operational plans without diluting equity or taking on external debt.
Plant Area: 5,000 Sq. metersCompletion Timeline: Within one monthCost of Acquisition: வெளியிடப்படவில்லைFunding Mode: Internal accruals
📅 குறுகிய காலம்Positive sentiment regarding manufacturing capacity additions, though visibility on the actual cash outlay is constrained as consideration value is not disclosed.
📈 நீண்ட காலம்Expands manufacturing footprint in Dahej, supporting volume growth in high-purity speciality fine chemicals over the coming quarters.
⚠ அபாய எச்சரிக்கைகள்
Regulatory approval risks (SEZ authority and Pollution Control Board approvals required)
Financial deal size/cost not disclosed in the filing
👀 கவனிக்க வேண்டியவை
Track the execution of definitive agreements and receipt of SEZ/Pollution Control regulatory approvals within the 1-month timeline, alongside future disclosures detailing the total acquisition cost and commercialization schedule.
Promoters Disclose Massive Stake Sale in Kronox Lab Sciences
Kronox Lab Sciences has submitted disclosures under SEBI PIT Regulations regarding significant equity stake sales by three key individuals/promoters. Jogindersingh Jaswal disclosed the sale of 97,96,400 equity shares (~23.09% of total paid-up equity). Concurrently, Ketan Ramani disclosed the sale of 97,96,400 shares (~23.09%), and Pritesh Ramani reported selling 67,11,200 shares (~18.09%). This represents a massive cumulative offloading of ownership, drastically reducing historical promoter holding from 74.21%.
உச்சம் நம்பிக்கை
என்ன மாறியதுKey insiders/promoters (Jogindersingh Jaswal, Ketan Ramani, Pritesh Ramani) offloaded major stakes totaling over 64% of the company's equity share capital.
ஏன் இது முக்கியம்A substantial divestment by founding or core promoters signals potential change in control, management restructuring, or significant dilution of promoter alignment with the business.
📅 குறுகிய காலம்Heavy supply overhang and potential volatility as the market digests substantial insider selling, with attention turning to block deal counterparty details.
📈 நீண்ட காலம்Significantly impacts governance and ownership structure; if taken over by a strategic or institutional investor, strategy execution (like UNIT-IV Dahej expansion) may be influenced by new stakeholders.
⚠ அபாய எச்சரிக்கைகள்
Massive promoter/insider divestment
Potential overhang and control uncertainty
👀 கவனிக்க வேண்டியவை
Track subsequent shareholding pattern filings and exchange bulk/block deal disclosures to identify the buyers (whether strategic, institutional, or open-market absorption) and assess potential management control shifts.
Kronox Lab Sciences has announced the completion of a major ownership change, with Indo Borax & Chemicals Limited acquiring 2,38,44,000 shares (64.26% stake) from the promoter sellers on September 29, 2026. Following the transaction, the erstwhile promoters retain a 9.95% stake and have stepped down from the promoter group and board positions. In their place, Suresh Kalra has been appointed MD & CEO alongside new executive and independent directors, while outgoing promoters have entered into 36-month transition consultancy agreements valued at ₹2.10 crore each.
உச்சம் நம்பிக்கை
என்ன மாறியதுControlling stake (64.26%) transferred from founding promoters to Indo Borax & Chemicals, triggering a total reconstitution of executive leadership and the board.
ஏன் இது முக்கியம்A complete change in promoters and C-suite leadership brings strategic realignments, operational synergies with Indo Borax, and alters corporate governance dynamics.
📅 குறுகிய காலம்Stock may witness volatility as markets digest the control shift, board overhaul, and potential open offer process.
📈 நீண்ட காலம்Performance will hinge on the incoming management team's ability to maintain high margins and execute ongoing capex such as UNIT-IV Dahej while integrating with Indo Borax.
⚠ அபாய எச்சரிக்கைகள்
Management transition and integration risks under new ownership
Related-party consultancy payments to outgoing promoters
👀 கவனிக்க வேண்டியவை
Track subsequent mandatory open offer disclosures and watch integration updates under the new Indo Borax-backed management, particularly execution progress on the Dahej UNIT-IV expansion.
Indo Borax files DLOF for ₹150.5 Cr Open Offer in Kronox Lab at ₹157.27/share
Kronox Lab Sciences Limited received the Draft Letter of Offer (DLOF) from IIFL Capital Services on behalf of Indo Borax and Chemicals Limited (Acquirer) and Zenrock Chemicals Private Limited (PAC). The open offer is to acquire up to 95,70,000 equity shares, representing 25.79% of the voting share capital (the entire public shareholding). The offer price is set at ₹157.27 per share payable in cash, representing an aggregate consideration of approximately ₹150.51 crore. The tendering period is tentatively scheduled to open on October 15, 2026, and close on October 29, 2026, subject to SEBI comments.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndo Borax and Chemicals, along with PAC, submitted the Draft Letter of Offer to SEBI to acquire up to 25.79% of Kronox Lab Sciences.
ஏன் இது முக்கியம்Triggers a potential change in control or substantial acquisition under SEBI SAST Regulations, giving public shareholders an exit window, though the offer price is currently at a discount to the market price.
Offer Price per share: ₹157.27Shares to be acquired: 95,70,000Offer Size (% of voting capital): 25.79%Tentative Offer Opening Date: அக்டோபர் 15, 2026Tentative Offer Closing Date: அக்டோபர் 29, 2026
📅 குறுகிய காலம்Stock may see trading action around the open offer price levels and upcoming regulatory approvals from SEBI.
📈 நீண்ட காலம்A change in strategic control or promoter backing by Indo Borax could alter business integration, synergy opportunities, and expansion plans like UNIT-IV.
⚠ அபாய எச்சரிக்கைகள்
Offer price of ₹157.27 is below the prevailing market price (₹184.70)
Subject to SEBI review and clearance of the Draft Letter of Offer
👀 கவனிக்க வேண்டியவை
Track SEBI comments on the DLOF (tentatively by September 28, 2026) and the Independent Directors Committee's recommendation by October 13, 2026. Note that the offer price of ₹157.27 is below the current market price of ₹184.70.
Indo Borax & Chemicals Issues Detailed Public Statement for Open Offer in Kronox Lab
Indo Borax and Chemicals Limited, along with Person Acting in Concert (PAC) Zenrock Chemicals Private Limited, has published a Detailed Public Statement (DPS) on August 28, 2026, for an Open Offer to acquire equity shares of Kronox Lab Sciences Limited. IIFL Capital Services Limited is acting as the Manager to the Open Offer pursuant to SEBI SAST Regulations. The formal publication was executed across national and regional daily editions on August 28, 2026. This signals a substantial acquisition or potential change in control structure.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndo Borax and Chemicals has officially triggered the public announcement phase for acquiring shares in Kronox Lab Sciences.
ஏன் இது முக்கியம்An open offer can alter the shareholding pattern, bring new strategic management, or provide an exit window for public shareholders depending on the offer price.
DPS Publication Date: ஆகஸ்ட் 28, 2026Promoter Holding: 74.21%Company Net Worth: Rs 116 கோடி
📅 குறுகிய காலம்The stock price is likely to trade in close correlation with the open offer price specified in the detailed public statement.
📈 நீண்ட காலம்Depending on whether this results in co-promotion or a full change in management, synergies with Indo Borax's chemical operations could shape future business scale.
⚠ அபாய எச்சரிக்கைகள்
Regulatory approvals required under SEBI Takeover Regulations
Open offer price vs prevailing market price dynamics
👀 கவனிக்க வேண்டியவை
Track the upcoming Letter of Offer to evaluate the specific open offer price, total offer size (% of share capital), and the tendering timeline.
Kronox Sets Sept 9, 2026 as Record Date for ₹0.50/Share Final Dividend
Kronox Lab Sciences Limited has fixed Wednesday, September 9, 2026, as the record date for its final dividend of ₹0.50 per equity share (face value ₹10 each) for FY 2025-26. The dividend was previously recommended by the Board on May 21, 2026, and is subject to shareholder approval. Investors holding shares on or prior to the record date will be eligible to receive the dividend payout.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company scheduled the official record date of September 9, 2026, for determining eligibility for the FY26 final dividend.
ஏன் இது முக்கியம்Confirms the timeline for cash distribution to shareholders following the FY26 dividend recommendation.
Final Dividend per share: ₹0.50முக மதிப்பு: ₹10ரெக்கார்ட் தேதி: 09-செப்.-2026
📅 குறுகிய காலம்Stock will trade ex-dividend around September 8-9, 2026, with eligible investors receiving the final dividend post-AGM approval.
📈 நீண்ட காலம்Limited; this is a standard corporate dividend distribution.
👀 கவனிக்க வேண்டியவை
Track shareholder approval at the upcoming Annual General Meeting and ensure shareholdings are settled before the ex-dividend date to be eligible for the payout.
Indo Borax to Acquire 64.26% Stake in Kronox Lab; Open Offer Launched at ₹157.27/share
Indo Borax and Chemicals Limited, along with PAC Zenrock Chemicals, has executed a Share Purchase Agreement to acquire a controlling 64.26% stake (2,38,44,000 shares) in Kronox Lab Sciences from its promoters at ₹103.22 per share. Following the agreement, an open offer has been announced to acquire up to 95,70,000 shares (25.79% of voting capital) from public shareholders at ₹157.27 per share. The sellers will also provide transition support consultancy services post-closing. IIFL Capital Services is acting as the manager to the offer.
உச்சம் நம்பிக்கை
என்ன மாறியதுPromoters of Kronox Lab Sciences agreed to sell 64.26% equity to Indo Borax and Chemicals, triggering a mandatory 25.79% open offer and a change of management control.
ஏன் இது முக்கியம்A complete shift in promoter ownership and control introduces a new strategic parent in specialty chemicals, potentially impacting strategic priorities such as the Dahej Unit-IV expansion.
SPA Stake Acquired: 64.26%SPA Price per Share: ₹103.22Open Offer Stake: 25.79%Open Offer Price per Share: ₹157.27Open Offer Shares Count: 95,70,000
📅 குறுகிய காலம்The market will digest the open offer price of ₹157.27 per share relative to the prevailing market price of ₹186.20 as the tendering schedule is finalized.
📈 நீண்ட காலம்Structural changes will depend on Indo Borax's integration plan, capital allocation strategy, and execution of Kronox's ongoing high-purity chemical expansion at Dahej Unit-IV.
⚠ அபாய எச்சரிக்கைகள்
Promoter transition and key personnel retention risk post-acquisition
Open offer price is at a discount to the recent market trading price
👀 கவனிக்க வேண்டியவை
Track the upcoming Detailed Public Statement (DPS), Letter of Offer, and the Kronox Independent Directors' Committee recommendation regarding the ₹157.27 open offer price.
September 09 Set as Record Date for Final Dividend for FY 2025-26
Kronox Lab Sciences has announced September 09, 2026, as the record date for determining shareholder eligibility for its final dividend for the financial year 2025-26. The dividend payout is contingent upon approval at the 17th Annual General Meeting (AGM) scheduled for September 16, 2026. The company's register of members will remain closed from September 10 to September 16, 2026. This routine corporate action follows a period of strong capital efficiency, with the company reporting a 36.0% ROCE and a minimal debt-to-equity ratio of 0.02.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has finalized the administrative timeline (record date and book closure) for its FY 2025-26 final dividend distribution.
ஏன் இது முக்கியம்This is a routine distribution of profits to shareholders, supported by the company's high purity specialty chemicals business which maintains a strong 36% ROCE.
ரெக்கார்ட் தேதி: செப்டம்பர் 09, 2026AGM Date: செப்டம்பர் 16, 2026Debt-to-Equity Ratio: 0.02ROCE: 36.0%Net Worth: Rs 116 கோடி
📅 குறுகிய காலம்The stock may trade with a focus on the dividend yield as the record date approaches, though the specific dividend amount was not detailed in this brief.
📈 நீண்ட காலம்Limited; this is a routine procedural filing. Long-term value remains tied to the successful expansion of manufacturing capacity at Dahej.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date (typically one business day prior to the record date). Monitor the upcoming AGM for updates on the operationalization of the Unit-IV facility at Dahej.
KRONOX Q1 Results: PAT Grows 14.6% YoY to ₹7.30 Cr; Record Date for Dividend Set
Kronox Lab Sciences reported a steady Q1 FY27 with revenue from operations growing 13.4% YoY to ₹28.31 Cr. Net profit (PAT) increased by 14.6% YoY to ₹7.30 Cr, maintaining a strong PAT margin of approximately 25.8%. The company has scheduled its 17th Annual General Meeting for September 16, 2026, and fixed September 09, 2026, as the record date for determining dividend eligibility. Additionally, the board approved the re-appointment of internal and cost auditors for the 2026-27 fiscal year.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its first-quarter financial performance for FY27 and formalized the timeline for its annual general meeting and dividend record date.
ஏன் இது முக்கியம்The results demonstrate the company's ability to maintain high margins (PAT >25%) in the specialty chemicals space, supported by its low debt (₹2 Cr) and high ROCE (36%).
📅 குறுகிய காலம்The stock may see positive sentiment due to the double-digit growth in both revenue and profit, alongside the upcoming dividend record date.
📈 நீண்ட காலம்The long-term outlook depends on the successful operationalization of Unit-IV at Dahej to scale its high-purity chemical portfolio for the pharmaceutical industry.
⚠ அபாய எச்சரிக்கைகள்
Slowdown in global pharmaceutical R&D spending
Potential delays in Unit-IV construction
Supply chain risks for specialized chemical precursors
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the Unit-IV expansion at Dahej, which is the primary driver for the company's targeted 15-20% growth rate. The upcoming AGM on September 16 will provide further clarity on dividend payouts and future capacity timelines.
Kronox Lab Sciences FY26 PAT Rises 8.6% to ₹27.66 Cr; Recommends ₹0.50 Final Dividend
Kronox Lab Sciences reported a steady financial performance for FY26, with annual revenue reaching ₹101.22 crore. The company's net profit for the full year grew by 8.6% to ₹27.66 crore, up from ₹25.46 crore in the previous fiscal. The fourth quarter was particularly strong, with PAT increasing to ₹8.00 crore compared to ₹6.32 crore YoY, despite flat revenue growth in the same period. To reward shareholders, the board has recommended a final dividend of ₹0.50 per equity share.
முக்கிய அம்சங்கள்
Annual Net Profit increased by 8.6% to ₹2,766.00 Lacs in FY26 from ₹2,545.71 Lacs in FY25Q4 FY26 PAT grew significantly to ₹800.21 Lacs versus ₹631.52 Lacs in the year-ago quarterFull-year Revenue from Operations stood at ₹10,122.00 Lacs, a marginal increase from ₹10,018.40 LacsBoard recommended a final dividend of ₹0.50 per equity share (5% of face value)Earnings Per Share (EPS) for FY26 improved to ₹7.51 from ₹6.81 in FY25
👀 கவனிக்க வேண்டியவை
The company shows strong margin improvement and consistent profit growth despite flat revenue, making it a positive hold for long-term investors. Monitor the upcoming AGM for dividend approval and management's outlook on future revenue scaling.
Kronox Lab Sciences Q3 FY26 PAT at ₹6.59 Cr; Revenue Grows 5.2% YoY to ₹25.27 Cr
Kronox Lab Sciences reported a steady but modest performance for the quarter ended December 31, 2025, with revenue from operations growing 5.2% YoY to ₹25.27 crore. Net profit for the quarter stood at ₹6.59 crore, showing a marginal increase from ₹6.53 crore in the same period last year. On a sequential basis, both revenue and profit saw a slight dip compared to the September 2025 quarter. For the nine-month period, the company maintained stability with a PAT of ₹19.66 crore compared to ₹19.15 crore in the previous year.
முக்கிய அம்சங்கள்
Revenue from operations increased to ₹2,527.40 lakhs in Q3 FY26 from ₹2,401.11 lakhs in Q3 FY25.Net Profit (PAT) for the quarter recorded at ₹658.90 lakhs, up marginally from ₹652.86 lakhs YoY.Total expenses for the quarter rose to ₹1,780.85 lakhs compared to ₹1,600.35 lakhs in the previous year's quarter.Nine-month (9M FY26) PAT reached ₹1,965.79 lakhs, representing a 2.6% growth over 9M FY25.Basic and Diluted Earnings Per Share (EPS) for the quarter stood at ₹1.78, compared to ₹1.77 in the year-ago period.
👀 கவனிக்க வேண்டியவை
The results indicate stable but slow growth with rising expenses impacting margins. Investors should maintain a hold position while monitoring the company's ability to scale revenue in the specialty chemicals segment.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
